HSD17B13 and metabolic dysfunction-associated steatohepatitis: Studies of HSD17B13 LOF and siRNA silencing of HSD17B13 mRNA found that hepatic steatosis was unaffected in subjects, and it was tentatively concluded that the lack of preventive effect of HSD17B13 on NASH and other related diseases is unlikely to be due to reduced metabolism of hepatic fat stores.